Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in Idiopathic Pulmonary Fibrosis (IPF)
NCT02688647Phase 2Completed
- Sponsor
- Kadmon
- Start
- May 2016
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belumosudil in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Kadmon. Primary endpoints: Change in Forced Vital Capacity at 24 weeks, Change in FVC% Predicted at 24 weeks and 1 more. Started May 2016; status: completed.
02
Drugs
belumosudil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02688647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688647.